RNA Therapeutics Could Cure Cancer and End All Rare Diseases -- with Professor Jeff Coller

Biotech CEO building an operating system for in vivo cell engineering -- Jay Rosanelli

Jay Rosanelli is the CEO and Co-Founder of Syenex, a biotech developing a platform for in vivo gene therapy delivery. While capital in the gene and cell therapy (CGT) space has grown over the last 5 years, there remain serious bottlenecks in delivery. In this conversation, we discuss what Syenex is building, the future of CGT, and what's next in AI-driven drug discovery and neurotech. Check out what Syenex is building: https://www.syenex.com/ 0:00 Introduction 0:55 Background 4:56 Biotech Capital 11:50 The Delivery Problem 17:37 Platform vs. Therapeutics 24:08 Partnership Model31:28 In-vivo CAR-T 37:49 Economics of Platform 42:08 AI x BIo 48:19 Future of BiotechABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.

Biotech Director at DARPA on Bio Innovation in Warfare in the Age of AI -- Michael Koeris

Michael Koeris is the Director of the Biological Technologies Office at DARPA, where he leads some of America's most cutting-edge biological research programs for defense. In this conversation, we discuss how AI is transforming warfare and what DARPA is doing to prepare for biological threats that may exist in the near future.

RNA Therapeutics Could Cure Cancer and End All Rare Diseases -- with Professor Jeff Coller

In this episode, I sit down with Jeff Coller, a professor at the Johns Hopkins University School of Medicine, about how decades of foundational RNA biology laid the groundwork for mRNA vaccines--and what comes next for medicine.Check out the Coller Lab: http://www.collerlab.org/0:00 Background2:21 Maternal RNA7:12 mRNA Stability 8:35 The 2015 Discovery 25:31 RNA Medicines35:18 Biotechnology 40:28 Biotech Startups46:39 Future of RNA Research ABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.

The Truth About Germline Editing Babies -- with Bioethicist John Quain

In this episode, I talk with John Quain, bioethics fellow at the Icahn School of Medicine and lead bioethicist at Manhattan Genomics. We talk about the ethics behind AI, germline editing, and the next wave of biotechnology. Check out the Manhattan Project: https://manhattangenomics.com/ 0:00 Intro 0:41 Background3:50 Artificial Intelligence 6:30 AGI11:16 AI in Medicine14:07 AI in Academic Science17:26 Germline Editing26:01 Pushback to Germline32:18 Future of Biotech EthicsABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.

Germline Editing Could Cost Less Than IVF — Cathy Tie

In this episode, biotech founder Cathy Tie unpacks the realities of building in regulated industries and the promise of gene editing done right. From unicorns and dragons to disease-free babies, we explore the technical, ethical, and economic future of germline correction.Check out the Manhattan Project: https://manhattangenomics.com/ 0:00 Intro 1:16 Ranomics7:53 Deep tech 10:40 Biotech challenges13:10 Locke Bio13:56 DTC Health 19:00 Personalized medicine 19:47 Marketing & Insurance 21:50 Germline Editing 26:30 Ethics of germline 31:06 Jiankui He 33:58 Designer babies 35:14 Cost of Germline 37:17 The Manhattan Project ABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.